BIOSTEM TECHN. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.14 USD | -9.66% |
|
-3.64% | +53.75% |
| 05-14 | Earnings Flash (BSEM) BIOSTEM TECHNOLOGIES Reports Q1 Revenue $41.9M | MT |
| 2023 | NovaBay to Commercialize BioStem's Amniotic Tissue Allograft | MT |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew van Vurst
FOU | Founder | - | 06/07/06 |
| Chief Executive Officer | - | 06/07/06 | |
| Director of Finance/CFO | - | 31/12/20 | |
Wendy Weston
CTO | Chief Tech/Sci/R&D Officer | 48 | 30/06/20 |
Joseph Babiak
CIO | Chief Investment Officer | - | - |
Dave Woynarowski
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/16 |
Ken Warrington
BRD | Director/Board Member | - | 28/10/19 |
| Sales & Marketing | - | - | |
Neal Bhattcharya
SAM | Sales & Marketing | - | 31/01/23 |
Larry Jones
PRN | Corporate Officer/Principal | - | 17/02/18 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Dugan
CHM | Chairman | 66 | 12-12 |
Patrick Daly
BRD | Director/Board Member | - | 12-18 |
| Chief Executive Officer | - | 06/07/06 | |
Andrew van Vurst
FOU | Founder | - | 06/07/06 |
Ken Warrington
BRD | Director/Board Member | - | 28/10/19 |
| - | - | ||
Brandon Poe
BRD | Director/Board Member | - | 06/09/22 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 0 | 5 | 0 | 0 | 99.00 % |
| Stock B | 1 | 16,214,390 | 16,052,246 ( 99.00 %) | 0 | |
| Stock C | 0 | 300 | 0 | 0 |
Company contact information
BioStem Technologies, Inc.
2836 Center Port Circle
33064, Pompano Beach
+954 380 8342
http://www.biostemtechnologies.com
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- Stock
- BSEM Stock
- Company BioStem Techn.
